ArticleOncology letters2026
Efficacy and safety of rituximab in the treatment of primary central nervous system lymphoma: A meta-analysis and systematic review of 1,388 patients.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of non-Hodgkin's lymphoma with a generally poor prognosis, and the median age at diagnosis is 65 years. The clinical value of rituximab in the treatment of PCNSL remains controversial. The present study aimed to evaluate the therapeutic benefits and safety of rituximab in patients with newly diagnosed PCNSL. The EMBASE, PubMed, Web of Science and Cochrane Library were systematically searched from database inception to May 5, 2025, without any language restrictions. Efficacy outcomes included complete remission (CR), overall survival (OS) and progression-free survival (PFS). Safety outcomes were assessed by adverse drug reactions. Statistical analysis was performed using Review Manager 5.3 and Stata16 software to calculate relative risks and 95% confidence intervals (CIs) for categorical data and to analyze survival data. The meta-analysis included 15 studies with 1,388 patients, with a relatively high proportion of males and elderly individuals, and comparable baseline characteristics between rituximab-containing chemotherapy group and the standard chemotherapy-alone control group. Compared with the control group, the rituximab combination group achieved a significantly improved 3-year OS, with an odds ratio (OR) of 2.01 (95% CI: 1.42-2.84, P<0.00001). The combined hazard ratio (HR) for OS was 0.57 (95% CI: 0.36-0.91, P=0.02). The 3-year PFS also showed significant improvement in the rituximab group with an OR of 2.3 (95% CI: 1.47-3.58, P=0.0002), and the combined PFS-HR was 0.54 (95% CI: 0.37-0.79, P=0.002). The rate of CR was significantly higher with an OR of 2.04 (95% CI: 1.5-2.77, P<0.00001). For safety outcomes, the OR for grade ≥3 leukopenia was 1.74 (95% CI: 0.92-3.27, P=0.09) and the OR for any-grade hepatic toxicity was 1.42 (95% CI: 0.98-2.05, P=0.06). In subgroup analyses, the OR for 3-year OS was 2.62 (95% CI: 1.16-5.91) for Asians and 1.69 (95% CI: 1.23-2.32) for Caucasians; the OR for 3-year PFS was 2.98 (95% CI: 1.17-7.6) for Asians and 2.02 (95% CI: 1.22-3.34) for Caucasians. In conclusion, based on this meta-analysis, rituximab significantly improved the prognosis of patients with PCNSL without a significant difference in safety compared to the existing treatment regimens. Further high-quality randomized controlled trials are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.